Market capitalization | $2.75b |
Enterprise Value | $2.80b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.59 |
P/S ratio (TTM) P/S ratio | 3.51 |
P/B ratio (TTM) P/B ratio | 11.91 |
Revenue growth (TTM) Revenue growth | 97.02% |
Revenue (TTM) Revenue | $781.37m |
As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.
23 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:
23 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 781 781 |
97%
97%
|
|
Gross Profit | 662 662 |
96%
96%
|
|
EBITDA | -163 -163 |
68%
68%
|
EBIT (Operating Income) EBIT | -165 -165 |
68%
68%
|
Net Profit | -198 -198 |
63%
63%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Head office | United States |
CEO | Cedric Francois |
Employees | 710 |
Founded | 2009 |
Website | www.apellis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.